title: A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics.
abstract: 1. The study evaluated the efficacy of amisulpride, fluoxetine and clomipramine at the beginning of the re-feeding phase of the treatment of restricting anorexia nervosa according to DSM-IV criteria. 2. 13 patients, mean weight 37.61 kg +/- 9.80 SD, were treated with clomipramine at a mean dosage of 57.69 mg +/- 25.79 SD; 10 patients, mean weight 40.90 kg +/- 6.98 SD, were treated with fluoxetine at a mean dosage of 28.00 mg +/- 10.32 SD; 12 patients, mean weight 38.41 kg +/- 8.33 SD, were treated with amisulpride at a mean dosage of 50.00 mg +/- 0.00 SD. 3. Clinical evaluation was carried out under single-blind condition at basal time and after three months by a structured clinical interview, the Eating Disorder Interview based on Long Interval Follow-up Evaluation (LIFE II BEI). 4. Patients treated with amisulpride showed a more significant increase (p=0.016) of mean weight. Concerning weight phobia, body image disturbance and amenorrhoea, no significant difference resulted.
authors.affiliation: Department of Clinical Psychiatry, University of Milan, Italy.
authors.forename: G M
authors.initials: GM
authors.lastname: Ruggiero
authors.forename: V
authors.initials: V
authors.lastname: Laini
authors.forename: M C
authors.initials: MC
authors.lastname: Mauri
authors.forename: V M
authors.initials: VM
authors.lastname: Ferrari
authors.forename: A
authors.initials: A
authors.lastname: Clemente
authors.forename: F
authors.initials: F
authors.lastname: Lugo
authors.forename: M
authors.initials: M
authors.lastname: Mantero
authors.forename: G
authors.initials: G
authors.lastname: Redaelli
authors.forename: D
authors.initials: D
authors.lastname: Zappulli
authors.forename: F
authors.initials: F
authors.lastname: Cavagnini
mesh_terms: D000328:Adult; D000568:Amenorrhea / Q000209:etiology; D000077582:Amisulpride; D000856:Anorexia Nervosa / Q000188:drug therapy* / Q000523:psychology; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000494:pharmacology*; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000494:pharmacology*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001828:Body Image; D002997:Clomipramine / Q000008:administration & dosage / Q000494:pharmacology*; D004035:Diet Therapy; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D016037:Single-Blind Method; D013469:Sulpiride / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D016896:Treatment Outcome; D015430:Weight Gain
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D005473:Fluoxetine; D013469:Sulpiride; D000077582:Amisulpride; D002997:Clomipramine